2023 World Conference on Lung Cancer (Posters)-EP11.03. Dose the Histological Subtype of NSCC-NOS Affect the Efficacy of 1st-Line PD-1/PD-L1 Inhibitors with or without Chemotherapy?

EP11.03. Dose the Histological Subtype of NSCC-NOS Affect the Efficacy of 1st-Line PD-1/PD-L1 Inhibitors with or without Chemotherapy? - PDF(Slides)

Back to course

Pdf Summary

This document is a summary of a study conducted to evaluate the association between the histological subtypes of non-small cell lung cancer (NSCLC) and the clinical efficacy of PD-1/PD-L1 inhibitors. The study included patients with advanced NSCLC who were treated with PD-1/PD-L1 inhibitors with or without chemotherapy between January 2016 and July 2022.<br /><br />The histological subtypes of NSCLC were determined based on morphological features and immunohistochemical markers. The subtypes included adenocarcinoma, squamous cell carcinoma, non-small cell carcinoma-not otherwise specified (NOS), NSCC-favor Ad, and NSCC-favor Sq.<br /><br />The results showed that the efficacy of PD-1/PD-L1 inhibitors for NSCC-NOS might be higher compared to other subtypes of NSCLC. The overall response rate (ORR) and disease control rate (DCR) were higher in NSCC-NOS compared to other subtypes.<br /><br />The study also analyzed the progression-free survival (PFS) and overall survival (OS) in NSCC-NOS and other subtypes. The PFS and OS rates were higher in NSCC-NOS compared to other subtypes, although the difference was not statistically significant.<br /><br />The study concluded that the histological subtype of NSCLC could be a useful factor for stratification in clinical trials of PD-1/PD-L1 inhibitors for advanced NSCLC.<br /><br />This research highlights the importance of considering the histological subtype of NSCLC when determining the efficacy of immune checkpoint inhibitors. The findings suggest that NSCC-NOS may have a better response to PD-1/PD-L1 inhibitors compared to other subtypes of NSCLC. Further studies are needed to validate these results and explore the underlying mechanisms.

Asset Subtitle

Tatsuya Hirano

Meta Tag

Speaker Tatsuya Hirano

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

non-small cell lung cancer

NSCLC

histological subtypes

PD-1/PD-L1 inhibitors

clinical efficacy

adenocarcinoma

squamous cell carcinoma

NSCC-NOS

overall response rate

disease control rate